Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Tang

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|June 30, 2025
Targeting the Hippo pathway in cancerKieran F Harvey, Tracy T Tang
Molecular Cancer Therapeutics|April 14, 2021
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of <i>NF2</i>-deficient MesotheliomaTracy T Tang, Andrei W Konradi, Ying Feng, et al.
The EMBO Journal|April 16, 2024
Non-vesicular phosphatidylinositol transfer plays critical roles in defining organelle lipid compositionYeun Ju Kim, Joshua G Pemberton, Andrea Eisenreichova, et al.
EMBO Reports|August 5, 2024
Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcriptionAishwarya Kulkarni, Varshini Mohan, Tracy T Tang, et al.
Nature Metabolism|March 3, 2026
Early-activated extracellular matrix proteins shape the metabolic and spatial dynamics of the kidney fibrotic microenvironmentYuan Gui, Wenxue Li, Jia-Jun Liu, et al.
Brain : a Journal of Neurology|September 23, 2022
Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningiomaLiyam Laraba, Lily Hillson, Julio Grimm de Guibert, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
The Journal of Clinical Investigation|July 2, 2026
Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma modelsMarco Jessen, KyungMok Kim, Marie Tollot-Wegner, et al.
Cancer Research|September 20, 2023
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor EfficacySuman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|June 30, 2025
Targeting the Hippo pathway in cancerKieran F Harvey, Tracy T Tang
Molecular Cancer Therapeutics|April 14, 2021
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of <i>NF2</i>-deficient MesotheliomaTracy T Tang, Andrei W Konradi, Ying Feng, et al.
The EMBO Journal|April 16, 2024
Non-vesicular phosphatidylinositol transfer plays critical roles in defining organelle lipid compositionYeun Ju Kim, Joshua G Pemberton, Andrea Eisenreichova, et al.
EMBO Reports|August 5, 2024
Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcriptionAishwarya Kulkarni, Varshini Mohan, Tracy T Tang, et al.
Nature Metabolism|March 3, 2026
Early-activated extracellular matrix proteins shape the metabolic and spatial dynamics of the kidney fibrotic microenvironmentYuan Gui, Wenxue Li, Jia-Jun Liu, et al.
Brain : a Journal of Neurology|September 23, 2022
Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningiomaLiyam Laraba, Lily Hillson, Julio Grimm de Guibert, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
The Journal of Clinical Investigation|July 2, 2026
Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma modelsMarco Jessen, KyungMok Kim, Marie Tollot-Wegner, et al.
Cancer Research|September 20, 2023
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor EfficacySuman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, et al.
Pageof 2